SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma

Published on 23 Jan 2025 on Zacks · via Yahoo Finance

The Sarclisa combination therapy was approved for a similar indication by the FDA in September, also...

Read the rest of the article

Start tracking your investments with Statfolio

The Sarclisa combination therapy was approved for a similar indication by the FDA in September, a...

Zacks · via Yahoo Finance 23 Jan 2025

Sanofi (SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly...

Seeking Alpha 22 Jan 2025

Maze Therapeutics and Metsera filed to list their stocks earlier in January. Like those two...

FierceBiotech 21 Jan 2025

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In thi...

Insider Monkey · via Yahoo Finance 21 Jan 2025

Verona Pharma stock jumped 10.6% that day. During an investor breakfast, company executives were...

Investor's Business Daily 16 Jan 2025

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a cor...

Motley Fool · via Yahoo Finance 16 Jan 2025

Merck is developing tulisokibart, a novel TL1A inhibitor, for the treatment of UC, CD and other...

Zacks · via Yahoo Finance 16 Jan 2025

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 mill...

Zacks · via Yahoo Finance 15 Jan 2025

France stocks higher at close of trade; CAC 40 up 0.20%

Investing.com 14 Jan 2025

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stag...

Zacks · via Yahoo Finance 14 Jan 2025